Access to the obesity medications known as GLP-1 receptor agonists has been a consistent problem for patients because of ...

NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.

Drugs like Wegovy and Ozempic have been in high demand after they were found to help in losing weight. But could a Trump ...

Novo Nordisk navigates competition and guidance challenges with strong profitability and upcoming oral Wegovy opportunities.

At a time when insurers are backing away from coverage for weight loss medications, President Trump has offered a lifeline ...

Those weight loss drugs that have been so out of reach for many, may soon be affordable, even if you don't have insurance.

People taking GLP-1 meds could see costs drop in 2026, thanks to a new federal deal with Eli Lilly and Novo Nordisk, the ...

Experts say the deal to lower the cost of the drugs is ambitious, but left some with more questions than answers.

The deal announced on Thursday, covering Novo's Wegovy and Lilly's Zepbound, will reduce monthly prices for U.S. government ...

The U.S. Food and Drug Administration said on Thursday it has awarded six more companies, including Eli Lilly and Novo ...